Abcam, ab257431, Human FABP5 knockout HeLa cell lysate

Size: 1Kit
FABP5 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon2 and 2 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon2 and 2 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FABP5, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The FABP5 protein also known as Fatty Acid Binding Protein 5 or Epidermal-type Fatty Acid Binding Protein (E-FABP) serves an important role in the transport and metabolism of long-chain fatty acids. It has a molecular mass of approximately 15 kDa. FABP5 is expressed in multiple tissues with notably high expression in the epidermis brain liver and adipose tissue. This protein assists in intracellular fatty acid movement affecting cellular lipid catabolism.
Biological function summary
FABP5 interacts with specific ligands such as long-chain fatty acids which influences cellular processes like growth differentiation and energy homeostasis. It is not known to be part of a larger complex. This protein is integral in regulating lipid signaling pathways and responses due to its binding capacity which modulates the availability of fatty acids for metabolic processes. Its expression pattern hints at a possible role in the body's adaptation to dietary lipid intake.
Pathways
FABP5 holds a significant position in the peroxisome proliferator-activated receptor (PPAR) signaling pathway and the fatty acid metabolism pathway. In the PPAR signaling pathway FABP5 influences the activity of PPARβ/δ receptors which regulate gene expression involved in lipid metabolism and energy homeostasis. It is related to other fatty acid binding proteins such as FABP4 which similarly participate in lipid metabolic processes and have roles in the regulation of lipid and glucose metabolism.
Researchers have linked FABP5 to conditions like psoriasis and type 2 diabetes. In psoriasis the overexpression of FABP5 has been observed in skin lesions suggesting that it might contribute to the pathological process. FABP5 is also connected to metabolic syndrome and insulin resistance as its dysregulation can influence lipid and glucose metabolism processes. In these disorders FABP5 interacts with proteins like PPARγ indicating possible intervention points for therapeutic targeting.